EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro activity of zoliflodacin against Neisseria gonorrhoeae collected in the United States from 2020 to 2022

Sarah M McLeod iD, Samir H Moussa iD, Meredith Hackel iD, Carmen Au, Pierre Daram

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.00527-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Sarah M McLeod und 4 weiteren Autor:innen. Beteiligte Einrichtung: Innoviva Specialty Therapeutics, Inc., an affiliate of Entasis Therapeutics Inc., Waltham, Massachusetts, USA. Hauptthemen laut MEDLINE: Neisseria gonorrhoeae, Anti-Bacterial Agents, Barbiturates. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zoliflodacin is a first-in-class spiropyrimidinetrione, oral, single-dose antibacterial recently approved by the US FDA for treatment of uncomplicated urogenital gonorrhea. Isolates of Neisseria gonorrhoeae ( n = 322) collected in the United States in 2020–2022 by the Centers for Disease Control and Prevention, as well as two ceftriaxone-resistant isolates, were tested for susceptibility to zoliflodacin. All isolates were susceptible to zoliflodacin with MIC 50/90 values of 0.12 µg/mL. Zoliflodacin activity was consistent over time and against ceftriaxone-, ciprofloxacin-, and tetracycline-resistant and azithromycin-non-susceptible isolates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neisseria gonorrhoeaeAnti-Bacterial AgentsBarbituratesMicrobial Sensitivity TestsUnited StatesGonorrheaHumansCiprofloxacinCeftriaxoneAzithromycinTetracyclineIsoxazolesMorpholinesSpiro CompoundsOxazolidinones

Stichwörter der Autor:innen

DNA gyraseNeisseria gonorrhoeaeantibiotic resistancegonorrheazoliflodacin

Substanzen

zoliflodacinAnti-Bacterial AgentsBarbituratesCiprofloxacinCeftriaxoneAzithromycinTetracyclineIsoxazolesMorpholinesSpiro Compounds

Autor:innen und Institutionen

  • Innoviva Specialty Therapeutics, Inc., an affiliate of Entasis Therapeutics Inc., Waltham, Massachusetts, USA.
  • IHMA, Inc., Schaumburg, Illinois, USA.
  • Global Antibiotic R&D Partnership, Geneva, Switzerland.

ORCID-Profile: Sarah M McLeod, Samir H Moussa, Meredith Hackel

Zitieren

APA

McLeod, S. M., Moussa, S. H., Hackel, M., Au, C., & Daram, P. (2026). In vitro activity of zoliflodacin against Neisseria gonorrhoeae collected in the United States from 2020 to 2022. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00527-26

Vancouver

McLeod SM, Moussa SH, Hackel M, Au C, Daram P. In vitro activity of zoliflodacin against Neisseria gonorrhoeae collected in the United States from 2020 to 2022. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00527-26

BibTeX
@article{McLeod2026,
  author = {McLeod, Sarah M and Moussa, Samir H and Hackel, Meredith and Au, Carmen and Daram, Pierre},
  title = {In vitro activity of zoliflodacin against Neisseria gonorrhoeae collected in the United States from 2020 to 2022},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.00527-26}
}
Kostenlos starten →